Empagliflozin + Linagliptin Tablets 10mg/5mg, 25mg/5mg Tablet

What is Empagliflozin + Linagliptin Tablets 10mg/5mg, 25mg/5mg Tablet?

Empagliflozin + Linagliptin Tablets combine empagliflozin, an SGLT2 inhibitor, with linagliptin, a DPP-4 inhibitor. Available in 10 mg/5 mg and 25 mg/5 mg strengths, this oral combination is used as part of the management of type 2 diabetes mellitus alongside appropriate diet and lifestyle measures.

Uses / Indications

Empagliflozin + Linagliptin Tablets may be used for:

• Management of type 2 diabetes mellitus
• Improving glycemic control in appropriate patients
• Combination therapy when treatment with one or more glucose-lowering medicines requires adjustment
• Use alongside diet and lifestyle measures as part of an overall diabetes management plan

This combination is not intended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Benefits

• Combines two complementary glucose-lowering mechanisms in one tablet.
• Empagliflozin promotes urinary glucose excretion through SGLT2 inhibition.
• Linagliptin enhances glucose-dependent insulin release and reduces glucagon secretion through DPP-4 inhibition.
• Available in two strengths: 10 mg/5 mg and 25 mg/5 mg.
• Provides a convenient oral fixed-dose combination for appropriate patients with type 2 diabetes.

Side Effects

Common Side Effects

Possible side effects may include:

• Increased urination
• Genital fungal infections
• Urinary tract infections
• Nasopharyngitis or upper respiratory symptoms
• Headache
• Gastrointestinal discomfort

Less Common or Serious Side Effects

Important but less common reactions may include dehydration, low blood pressure, ketoacidosis, serious urinary or genital infections, pancreatitis, severe hypersensitivity reactions, and severe joint or muscle-related reactions. Patients should seek prompt medical attention for symptoms such as severe abdominal pain, persistent vomiting, difficulty breathing, confusion, or signs of a serious infection or allergic reaction.

How Does It Work?

Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing renal glucose reabsorption and increasing urinary glucose excretion. Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing the activity of incretin hormones and thereby supporting glucose-dependent insulin secretion while reducing glucagon release.

Dosage Guidelines

The appropriate regimen should be determined according to the approved product information and the individual patient’s clinical circumstances.

• Available strengths are empagliflozin 10 mg/linagliptin 5 mg and empagliflozin 25 mg/linagliptin 5 mg.
• The usual dosing schedule and any adjustment should follow approved prescribing information.
• Renal function should be considered when determining whether empagliflozin-containing therapy is appropriate.
• The tablet should be taken exactly as directed by a healthcare professional.
• Do not change the strength or dose without appropriate medical advice.

When Not to Use

Empagliflozin + Linagliptin should not be used in certain circumstances, including:

• Known serious hypersensitivity to empagliflozin, linagliptin, or any component of the product
• Diabetic ketoacidosis
• Type 1 diabetes mellitus
• Certain severe renal impairment situations where empagliflozin is not appropriate
• Other contraindicated conditions specified in the approved product information

Drug / Product Interactions

Potential interactions may occur with:

• Insulin and insulin secretagogues, which may increase the risk of hypoglycemia
• Diuretics, which may contribute to volume depletion
• Certain medicines affecting renal function or fluid balance
• Strong enzyme inducers that may reduce exposure to linagliptin

A complete medication history should be reviewed before starting or changing therapy.

Safety Advice

• Monitor blood glucose as recommended by the healthcare professional.
• Maintain adequate hydration unless fluid restriction has been advised.
• Be alert for symptoms of ketoacidosis, including nausea, vomiting, abdominal pain, unusual tiredness, or difficulty breathing.
• Monitor for urinary and genital infections.
• Inform the healthcare professional before major surgery or prolonged fasting.
• Hypoglycemia may occur, particularly when used with insulin or insulin secretagogues.
• Report symptoms suggestive of pancreatitis, such as persistent severe abdominal pain.
• Kidney function should be assessed as clinically appropriate.

General Instructions

• Take the tablet exactly as prescribed.
• The tablet may generally be taken with or without food according to the approved product information.
• Swallow the tablet as directed; do not alter the dosage form unless instructed.
• Maintain recommended fluid intake unless otherwise advised.
• Continue appropriate dietary and lifestyle measures.
• Do not discontinue diabetes treatment or change the strength without professional guidance.
• Product details should be confirmed against the approved product specification.

Special Dietary / Lifestyle Tips

• Follow an appropriate balanced diet recommended for diabetes management.
• Maintain regular physical activity where medically appropriate.
• Maintain adequate hydration.
• Monitor blood glucose according to the recommended schedule.
• Limit excessive alcohol intake, particularly where it may contribute to dehydration or metabolic complications.
• Follow regular medical monitoring as advised.

Comparison with Other Treatments

Empagliflozin + Linagliptin combines an SGLT2 inhibitor with a DPP-4 inhibitor, providing two different approaches to glucose management. Other antidiabetic treatments, such as metformin, insulin, sulfonylureas, GLP-1 receptor agonists, or other SGLT2 inhibitors, have different mechanisms, benefits, precautions, and monitoring requirements. Treatment selection depends on individual clinical factors and the approved therapeutic guidance.

Precautions & Warnings

• Assess renal function before and during treatment as appropriate.
• Consider the risk of volume depletion, especially in patients taking diuretics or those susceptible to dehydration.
• Be alert for ketoacidosis, which can occur even when blood glucose is not markedly elevated.
• Temporary interruption may be appropriate in situations such as prolonged fasting, major surgery, or acute serious illness, according to professional advice.
• Monitor for genital and urinary tract infections.
• Patients with a history of pancreatitis should discuss appropriate treatment options with a healthcare professional.
• Hypoglycemia risk may increase when combined with insulin or insulin secretagogues.
• Use during pregnancy or breastfeeding should be discussed with an appropriate healthcare professional.

Can I Use It With Other Medicines?

Generally Compatible With

Empagliflozin + Linagliptin may be used with other glucose-lowering medicines when specifically prescribed and monitored. The combination may be incorporated into a broader diabetes treatment plan according to approved indications.

Use With Caution / Avoid

Particular caution may be required with:

• Insulin
• Sulfonylureas and other insulin secretagogues
• Diuretics
• Medicines affecting fluid balance or renal function
• Strong enzyme-inducing medicines that may affect linagliptin exposure

All concurrent medicines should be reviewed by a healthcare professional.

Storage

Store according to the approved product label and packaging instructions. Keep the tablets protected from unsuitable environmental conditions and out of reach of children. Do not use the product after the stated expiry date.

Frequently Asked Questions

1. What is Empagliflozin + Linagliptin 10 mg/5 mg and 25 mg/5 mg used for?

It is an oral antidiabetic combination used in the management of type 2 diabetes mellitus.

2. What are the available strengths?

The product is available as empagliflozin 10 mg + linagliptin 5 mg and empagliflozin 25 mg + linagliptin 5 mg.

3. How does Empagliflozin work?

Empagliflozin inhibits SGLT2 in the kidneys, increasing urinary glucose excretion and thereby reducing blood glucose levels.

4. How does Linagliptin work?

Linagliptin inhibits DPP-4, helping increase incretin activity and supporting glucose-dependent insulin secretion while reducing glucagon release.

5. Is this medicine used for type 1 diabetes?

No. Empagliflozin + Linagliptin is used for type 2 diabetes and is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

6. What are common side effects?

Possible side effects include increased urination, genital fungal infections, urinary tract infections, upper respiratory symptoms, and headache.

7. Can this medicine cause low blood sugar?

The risk of hypoglycemia can increase when the combination is used with insulin or insulin secretagogues. Appropriate monitoring and dose adjustment may be required.

8. What is the supplied packing?

The supplied packing is 9×10 Alu-Pvc Blister / As per your requirement. Product details should be confirmed against the approved product specification.